Compare HLN & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLN | ONC |
|---|---|---|
| Founded | 2022 | 2010 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7B | 34.8B |
| IPO Year | N/A | N/A |
| Metric | HLN | ONC |
|---|---|---|
| Price | $9.50 | $322.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $369.50 |
| AVG Volume (30 Days) | ★ 9.3M | 332.2K |
| Earning Date | 07-31-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 41.64 | N/A |
| EPS | 0.23 | ★ 0.58 |
| Revenue | ★ $15,096,588,575.00 | $4,972,687,000.00 |
| Revenue This Year | $1.51 | $36.37 |
| Revenue Next Year | $4.67 | $22.04 |
| P/E Ratio | ★ $20.52 | $521.25 |
| Revenue Growth | N/A | ★ 50.43 |
| 52 Week Low | $8.71 | $170.99 |
| 52 Week High | $11.42 | $385.22 |
| Indicator | HLN | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 42.54 |
| Support Level | $9.69 | $325.00 |
| Resistance Level | $9.77 | $340.98 |
| Average True Range (ATR) | 0.13 | 13.32 |
| MACD | -0.04 | -3.46 |
| Stochastic Oscillator | 2.27 | 16.88 |
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.